Article -> Article Details

The global anti-epilepsy drugs market is expected to exhibit a solid 3.79% CAGR over the forecast period from 2016 to 2022, according to the latest research report from Market Research Future (MRFR). The global anti-epilepsy drugs market was valued at USD 3.7 billion in 2015 and is expected to reach USD 4.8 billion by 2022. The report presents a comprehensive overview of the global anti-epilepsy drugs market, including a detailed analysis of the market’s major drivers and restraints, major players, and other factors and trends affecting the market’s movement. The short-term and long-term impact of the coronavirus pandemic on the anti-epilepsy drugs market is also studied in the report. 

Anti-epilepsy drugs are drugs formulated to counter epilepsy, a neurological disorder characterized by seizures. The rising prevalence of epilepsy and rising awareness about the disease are likely to be the major drivers for the global anti-epilepsy drugs market over the forecast period. Around 24 million people around the world suffer from epilepsy. Rising awareness about the disease is a major driver for the global anti-epilepsy drugs market. Due to its puzzling origins, epilepsy has always been shrouded in mystery. 

Get Sample Copy of Report @ https://www.marketresearchfuture.com/sample_request/2345 

This has led to a lack of awareness about effective cures for the condition. However, this condition has reversed in the last few decades, with the development of effective treatments for the disease resulting in growing awareness around the world. This is likely to remain a major driver for the global anti-epilepsy drugs market over the forecast period. 

On the other hand, the unknown origin of epilepsy is likely to remain a key restraint on the global anti-epilepsy drugs market, as this makes it difficult to develop effective cures against the disease. Despite growing research, the origins of epilepsy have remained elusive, making it difficult to develop effective cures. The loss of patents of anti-epilepsy drugs such as Neurontin and Lyrica is also likely to be a major restraint on the global anti-epilepsy drugs market over the forecast period. 

Competitive Leaderboard:

Leading players in the global anti-epilepsy drugs market include Cephalon Inc., Shire Pharmaceuticals Ltd., Sanofi SA, Novartis International AG, GSK plc, Abbott Laboratories, UCB Pharma Ltd., Johnson & Johnson, and Pfizer Inc. Major players in the global anti-epilepsy drugs market are likely to engage in product development in the coming years, as the development of effective anti-epilepsy drugs has become attainable for players in the market. The development of generics is also likely to remain a major trend in the global anti-epilepsy drugs market over the forecast period. 

Segmentation:

The global anti-epilepsy drugs market is segmented on the basis of type of seizure, generation, and region. 

• By Type of Seizure, the global anti-epilepsy drugs market is segmented into generalized seizures and partial-onset seizures. 
• By Generation, the global anti-epilepsy drugs market is segmented into first-generation, second-generation, and third-generation anti-epilepsy drugs. Third-generation anti-epilepsy drugs are likely to carve out an important share in the global anti-epilepsy drugs market over the forecast period. 

Get Access Full Report @ https://www.marketresearchfuture.com/reports/anti-epilepsy-drugs-market-2345 

Regional Analysis:

The Americas and Europe dominate the global anti-epilepsy drugs market with an almost equal share. However, over the forecast period, the Americas market is likely to exhibit higher growth, with the Americas market pulling ahead of Europe by 2022. North America is the major regional market within the Americas and is likely to remain the major revenue generator over the forecast period. 

The U.S. is likely to remain the leading regional market over the forecast period due to the easy availability of advanced anti-epilepsy therapeutics in the region and the growing awareness about anti-epilepsy drugs in the region. The presence of leading anti-epilepsy drugs market players in the region has led to a growing presence of the market in the region, leading to the region establishing a strong share in the global anti-epilepsy drugs market. Europe is also an important regional market for anti-epilepsy drugs.